AXSM Axsome Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AXSM

Price (delayed)

$72.5

Market cap

$3.44B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.43

Enterprise value

$3.3B

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people ...

Highlights
The revenue has soared by 74% YoY but it has contracted by 7% from the previous quarter
AXSM's gross profit has surged by 72% year-on-year but it is down by 7% since the previous quarter
The net income has plunged by 87% YoY and by 24% from the previous quarter
The EPS has plunged by 68% YoY and by 22% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.axsome.com
Peers: OMER OMGA

Key stats

What are the main financial stats of AXSM
Market
Shares outstanding
47.5M
Market cap
$3.44B
Enterprise value
$3.3B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
23.85
Price to sales (P/S)
13.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.15
Earnings
Revenue
$251.02M
EBIT
-$292.73M
EBITDA
-$284.23M
Free cash flow
-$193.34M
Per share
EPS
-$6.43
Free cash flow per share
-$4.08
Book value per share
$3.04
Revenue per share
$5.3
TBVPS
$10.17
Balance sheet
Total assets
$545.73M
Total liabilities
$401.69M
Debt
$188.8M
Equity
$144.04M
Working capital
$316.44M
Liquidity
Debt to equity
1.31
Current ratio
3.2
Quick ratio
3.01
Net debt/EBITDA
0.5
Margins
EBITDA margin
-113.2%
Gross margin
90.1%
Net margin
-118.1%
Operating margin
-116.6%
Efficiency
Return on assets
-50.5%
Return on equity
-134.2%
Return on invested capital
-157.5%
Return on capital employed
-72.9%
Return on sales
-116.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXSM stock price

How has the Axsome Therapeutics stock price performed over time
Intraday
-1.6%
1 week
-3.07%
1 month
2.16%
1 year
-9.62%
YTD
-8.91%
QTD
-9.15%

Financial performance

How have Axsome Therapeutics's revenue and profit performed over time
Revenue
$251.02M
Gross profit
$226.22M
Operating income
-$292.73M
Net income
-$296.38M
Gross margin
90.1%
Net margin
-118.1%
The company's operating income has shrunk by 98% YoY and by 26% QoQ
The net income has plunged by 87% YoY and by 24% from the previous quarter
The revenue has soared by 74% YoY but it has contracted by 7% from the previous quarter
AXSM's gross profit has surged by 72% year-on-year but it is down by 7% since the previous quarter

Growth

What is Axsome Therapeutics's growth rate over time

Valuation

What is Axsome Therapeutics stock price valuation
P/E
N/A
P/B
23.85
P/S
13.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.15
The EPS has plunged by 68% YoY and by 22% from the previous quarter
The P/B is 37% lower than the 5-year quarterly average of 37.9 but 37% higher than the last 4 quarters average of 17.4
The equity has increased by 29% year-on-year but it has declined by 25% since the previous quarter
The revenue has soared by 74% YoY but it has contracted by 7% from the previous quarter
The price to sales (P/S) is 9% lower than the last 4 quarters average of 15.1

Efficiency

How efficient is Axsome Therapeutics business performance
The ROS has contracted by 36% from the previous quarter and by 14% YoY
The ROE has contracted by 19% from the previous quarter but it has grown by 17% YoY
AXSM's ROA is down by 16% QoQ
The company's return on invested capital fell by 14% QoQ but it rose by 10% YoY

Dividends

What is AXSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXSM.

Financial health

How did Axsome Therapeutics financials performed over time
Axsome Therapeutics's total assets is 36% more than its total liabilities
AXSM's total liabilities is up by 45% year-on-year
Axsome Therapeutics's total assets has increased by 40% YoY but it has decreased by 7% from the previous quarter
Axsome Therapeutics's debt is 31% higher than its equity
The debt to equity has increased by 34% QoQ
The equity has increased by 29% year-on-year but it has declined by 25% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.